25.9 C
New York
Tuesday, June 9, 2026

Tag: investment strategy

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor...

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor...

CSOP Hosts Hong Kong – Korea Capital Markets Conference in Seoul; Financial Secretary Paul Chan Highlights Hong Kong’s Advantages to Korean Institutional Investors

SEOUL, South Korea, July 9, 2025 /PRNewswire/ -- On the morning of July 9, 2025, CSOP Asset Management Limited (CSOP), Asia's leading ETF issuer, successfully...

Blue Owl Capital Launches U.S. Diversified Direct Lending Strategy with Australia’s Koda Capital

Blue Owl Credit Income Fund AUT (OCIC-A) now available to Australian financial advisors and their clients in partnership with Australia's largest independent wealth management...

Orchid Island Capital to Announce Second Quarter 2025 Results

VERO BEACH, Fla., July 07, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced that it will release results for the second quarter of 2025 following the close of trading on the New York Stock Exchange on Thursday, July 24, 2025.

MSTR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MicroStrategy Incorporated d/b/a Strategy Investors with Substantial Losses Have Opportunity to Lead Class Action...

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy (“Strategy” or “the Company”) (NASDAQ: MSTR) and certain of its officers.

Oxford Business Group and Oman Investment Authority highlight sultanate’s economic transformation in new advisory report

Strategic investment in focus as Oman accelerates diversification MUSCAT, Oman, July 3, 2025 /PRNewswire/ -- Oman's efforts to accelerate economic diversification through targeted investment in...

Addentax Group Corp. Enters Into US$1.3 Billion Term Sheet for Proposed Acquisition of Up to 12,000 Bitcoins

SHENZHEN, China, July 2, 2025 /PRNewswire/ -- Addentax Group Corp. (Nasdaq: ATXG) (the "Company") today announced that it has entered into a non-binding term...

EV Tax Credit Termination Post-September—Evaluating Implications for Investment Strategy

The recent passage of a tax-and-spending package, supported by President Trump and narrowly approved by the Senate, has significant implications for the electric vehicle...

Kayne Anderson Energy Infrastructure Fund Provides Unaudited Balance Sheet Information and Announces Its Net Asset Value and Asset Coverage Ratios as of June 30,...

HOUSTON, July 01, 2025 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of June 30, 2025.

Novo Holdings portfolio company Kate Farms acquired by Danone

Novo Holdings led Kate Farms' Series C financing in 2022 and supported its continued growth as the company's largest institutional investor Transaction highlights the Planetary...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.

E-L Financial Corporation Limited Enters Into Automatic Share Purchase Plan

TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- E-L Financial Corporation Limited (TSX:ELF) (TSX:ELF.PR.F) (TSX:ELF.PR.G) (TSX:ELF.PR.H) (the “Company”) announced today that, as part of its previously announced normal course issuer bid (the “Bid”), it has entered into a pre-defined automatic share purchase plan (“ASPP”) with its designated broker in order to facilitate repurchases of the Company’s common shares (the “Shares”). The ASPP has received clearance from the Toronto Stock Exchange (the “Exchange”) and is scheduled to take effect on June 30, 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInvestment strategy